PET放射性代谢物的化学鉴定及其对成像的影响
该综述聚焦PET示踪剂在体内经氧化还原、水解、脱羧及结合等生物转化后产生的放射性代谢物,强调需定量母体示踪剂在血浆和组织中的比例,并列举[11C]PBB3、[11C]flumazenil、[18F]FEPE2I、[11C]PBR28、[11C]MADAM和(+)[18F]flubatine的代谢物化学结构鉴定,指出轻微化学修饰可减少干扰性代谢物形成。
要点
- PET测得信号反映组织总放射性,不能区分母体示踪剂与放射性代谢物。
- 需定量血浆母体示踪剂比例,并排除或校正代谢物在外周组织的累积。
- 轻微化学修饰可减少放射性代谢物形成,从而降低对PET结果的干扰。
核心结论
- 放射性代谢物的化学鉴定对PET成像至关重要,可用于确定血浆母体示踪剂含量并排除或校正组织代谢物累积。
研究设计与样本
- 综述类文章,汇总多种PET示踪剂放射性代谢物的化学与结构鉴定信息。
主要发现
- PET示踪剂在体内经氧化还原、水解、脱羧及各种结合过程发生生物转化,母体示踪剂数量下降。
- PET扫描仪测得信号代表组织沉积的总放射性,不提供母体示踪剂化学状态的信息。
- 放射性代谢产物在体内的分布模式可能与示踪剂本身显著不同。
关键数值与推荐
- 文章汇总了[11C]PBB3、[11C]flumazenil、[18F]FEPE2I、[11C]PBR28、[11C]MADAM和(+)[18F]flubatine的放射性代谢物化学与结构特征。
临床怎么用
- 解读PET图像时应考虑放射性代谢物对组织信号的可能贡献,必要时进行代谢物校正。
- 示踪剂研发中可通过轻微化学修饰减少干扰性放射性代谢物的形成。
局限性
- 本文为综述,未报告原始实验数据、样本量或定量阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Positron emission tomography (PET) offers the study of biochemical, physiological, and pharmacological functions at a cellular and molecular level. The performance of a PET study mostly depends on the used radiotracer of interest. However, the development of a novel PET tracer is very difficult, as it is required to fulfill a lot of important criteria. PET radiotracers usually encounter different chemical modifications including redox reaction, hydrolysis, decarboxylation, and various conjugation processes within living organisms. Due to this biotransformation, different chemical entities are produced, and the amount of the parent radiotracer is declined. Consequently, the signal measured by the PET scanner indicates the entire amount of radioactivity deposited in the tissue; however, it does not offer any indication about the chemical disposition of the parent radiotracer itself. From a radiopharmaceutical perspective, it is necessary to quantify the parent radiotracer's fraction present in the tissue. Hence, the identification of radiometabolites of the radiotracers is vital for PET imaging. There are mainly two reasons for the chemical identification of PET radiometabolites: firstly, to determine the amount of parent radiotracers in plasma, and secondly, to rule out (if a radiometabolite enters the brain) or correct any radiometabolite accumulation in peripheral tissue. Besides, radiometabolite formations of the tracer might be of concern for the PET study, as the radiometabolic products may display considerably contrasting distribution patterns inside the body when compared with the radiotracer itself. Therefore, necessary information is needed about these biochemical transformations to understand the distribution of radioactivity throughout the body. Various published review articles on PET radiometabolites mainly focus on the sample preparation techniques and recently available technology to improve the radiometabolite analysis process. This article essentially summarizes the chemical and structural identity of the radiometabolites of various radiotracers including [11C]PBB3, [11C]flumazenil, [18F]FEPE2I, [11C]PBR28, [11C]MADAM, and (+)[18F]flubatine. Besides, the importance of radiometabolite analysis in PET imaging is also briefly summarized. Moreover, this review also highlights how a slight chemical modification could reduce the formation of radiometabolites, which could interfere with the results of PET imaging.
引用
- Ghosh KK, Padmanabhan P, Yang CT, et al. Dealing with PET radiometabolites. EJNMMI Res. 2020. PMID: 32997213. doi:10.1186/s13550-020-00692-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。